Oscar Health, Inc.

Based on the provided analysis, here is a comprehensive evaluation of OSCR.

Technical Analysis OSCR's technical picture is concerning, characterized by significant underperformance and high volatility. The stock trades much closer to its 52-week low than its high, and while this may suggest it is oversold, its exceptionally high beta of 1.9 indicates it remains highly sensitive to broad market swings. The recent sharp monthly decline confirms persistent near-term weakness.

Fundamental Analysis Fundamentally, OSCR is facing severe operational challenges. Revenue is declining, and profitability has collapsed with deeply negative net income and ROE, indicating the company is struggling to convert sales into profit. While the balance sheet shows low debt, a current ratio below 1.0 points to potential liquidity constraints despite adequate cash flow coverage.

Valuation & Risk Valuation metrics are negative due to the lack of earnings, making traditional P/E analysis impractical and underscoring the core problem of unprofitability. The primary risk is extreme volatility; the high beta and severe maximum drawdown mean the stock is prone to rapid, deep losses, which also introduces liquidity risk for investors.

---

Investment Recommendation

OSCR is currently a high-risk proposition with significant fundamental headwinds. The severe deterioration in revenue and profitability, coupled with extreme price volatility, presents substantial downside risk. While the low debt level offers some financial stability, investors should wait for clear evidence of a turnaround in operational performance before considering a position. At this time, the stock is not recommended for purchase by most investors.

RockFlow Model Forecast: Three Scenarios for 2026

Based on the comprehensive analysis, the 12-month outlook for OSCR is bearish, with significant challenges outweighing potential for a near-term recovery.

The key catalyst for any positive move would be concrete evidence of an operational turnaround, such as a return to revenue growth or a credible path to profitability. However, the primary risks dominate the outlook, including the continued deterioration in fundamentals, extreme volatility (high beta), and potential liquidity constraints. Given the severe fundamental headwinds and lack of analyst coverage providing a target price, the stock carries substantial downside risk.

Consequently, a target price range is not appropriate as the company's valuation is challenged by a lack of earnings. Investors should await demonstrable improvements in the company's core operations before considering a position.

Wall Street Consensus

Most Wall Street analysts are optimistic about Oscar Health, Inc.'s 12-month outlook, with consensus target around $13.64, indicating expected upside potential.

Overall, OSCR has investment potential but also faces challenges. Here are key factors to weigh before investing.

OSCR has demonstrated significant volatility with substantial declines over the past year despite recent stabilization.

The stock has been under pressure with a sharp 9.08% decline over the past month, though it has managed to edge up 0.3% over three months, underperforming the broader market by 3.43% during that period, indicating persistent weakness in the near term.

Currently trading at $13.52, OSCR sits closer to its 52-week low of $11.2 than its high of $23.8, suggesting the stock may be in oversold territory, though its high beta of 1.898 indicates continued vulnerability to market swings.

Revenue & Profitability OSCR's Q4 2025 revenue declined to $2.8B from $3.0B in the prior quarter, reflecting negative growth momentum. Profitability deteriorated significantly, with the gross profit margin collapsing to 6.6% from 13.4% and the net income margin deepening to -12.6% amid substantial operating losses.

Financial Health The company maintains a low debt ratio of 6.8% and a manageable debt-to-equity of 0.44, indicating minimal leverage risk. However, the current ratio of 0.95 signals potential liquidity constraints, though strong operating cash flow coverage ratios suggest adequate cash generation relative to obligations.

Operational Efficiency OSCR demonstrates poor operational efficiency with a deeply negative ROE of -36.1% and weak asset turnover of 0.44, highlighting ineffective utilization of equity and assets. The negative operating income margin confirms fundamental operational challenges in converting revenue into profits.

Given the negative trailing and forward P/E ratios, OSCR appears to be in a period of unprofitability rather than being overvalued or undervalued in the traditional sense. Negative valuation metrics generally indicate that the company is not currently generating positive earnings, making a standard valuation assessment based on earnings multiples impractical. Investors should focus on the drivers of these losses and the path to future profitability rather than a simple P/E comparison.

In the absence of industry average data, a peer comparison cannot be quantitatively substantiated. Therefore, analysis must rely on the qualitative implications of the negative EV/EBITDA and P/E ratios, which suggest OSCR is underperforming relative to the fundamental expectation of profitability that typically defines its sector. A meaningful valuation assessment relative to peers requires obtaining current industry benchmark data for a proper comparative analysis.

Volatility Risk: OSCR exhibits substantial volatility risk, evidenced by its exceptionally high beta of 1.898, implying it is nearly twice as volatile as the broader market. This elevated sensitivity is further confirmed by a severe one-year maximum drawdown of -45.53%, indicating a significant potential for rapid and deep losses during market downturns.

Other Risks: The notable absence of reported short interest mitigates one immediate pressure but may obscure speculative risks or signal low market attention. However, the extreme price volatility itself creates a high liquidity risk, as large price swings can lead to wider bid-ask spreads and difficulty executing trades at desired prices, particularly for larger positions.